Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clarithromycin-based vs levofloxacin-based quadruple therapy for Helicobacter pylori eradication
IRCT20200929048884N1Phase 3Completed
- Sponsor
- Qom University of Medical Sciences
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of clarithromycin and levofloxacin in Helicobacter pylori infection (2 arms), sponsored by Qom University of Medical Sciences. Primary endpoint: Helicobacter pylori eradication rate. Started Oct 2020; status: completed.
02
Drugs
clarithromycinlevofloxacin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20200929048884N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200929048884N1.